Key Points Interested in Surrozen, Inc.? Here are five stocks we like better. Surrozen is advancing a Wnt-based retina ...

The Wnt signaling pathway, a system present in living organisms, plays a pivotal role in cell growth, differentiation, and migration. It has a long history dating back to 1982, when the first Wnt gene ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide and renew themselves. Decades of research have shown that disruption of this pathway is a ...

Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar beginning at ...

A Wnt/β-catenin pathway agonist under development by Surrozen appears to be effective against idiopathic pulmonary fibrosis (IPF) in mouse models, according to new data. The results, published April 2 ...

Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the ...